Mazor Surgical Technologies Ltd. (TASE:MZOR) share rose 11.8% today to NIS 9.85, giving a market cap of NIS 200 million, after IBI Investment House Ltd. gave it a "Buy" recommendation. IBI set a target price of NIS 15.70.

Analyst Natalie Gottlieb explained that the company's development of advanced imaging devices and robotics for surgery makes it one of the most interesting biomed companies traded on the TASE.

Mazor has three devices already approved for marketing: SpineAssist, which performs robotic surgery and has already recorded several million dollars worth of sales; C-Insight, which performs 3D imaging for the surgical theater; and GO-LIF with unique screws for the spinal column.

According to IBI, 2010 will be a year of major development for Mazor with rapid marketing of its new products a strong possibility, though she warned that slow, ineffective marketing was still a significant risk.

IBI added that Mazor's target for 2010 is the signing of a strategic marketing agreement for C-Insight, receipt of approval from the US Food and Drugs Administration (FDA) for GO-LIF, and expanded sales in Europe for SpineAssist.

Published by Globes [online], Israel business news - www.globes-online.com - on February 23, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010